Instrument Inactif

Communiqués King Pharmaceuticals, Inc.

Actions

KG

US4955821081

Recherche biotechnologique et médicale

Cours en clôture NYSE
- ^USD	-

01/09/10	KING PHARMA : L'américain Burger King envisagerait de se vendre	RE
13/11/09	KING PHARMA : Burger King veut ouvrir son premier restaurant en Russie en 2009	RE

Communiqués

20/12/10	KING PHARMA : King Pharmaceuticals and Acura Pharmaceuticals Announce Submission of New Drug Application for ACUROX® Tablets	PR
13/10/10	KING PHARMA : The Law Office of Abe Shainberg is Launching an Investigation into the Possible Breaches of Fiduciary Duty by the Board of King Pharmaceuticals, Inc. in Connection with the Sale of the Company to Pfizer, Inc. – KG	BU
13/10/10	KING PHARMA : Law Office of Brodsky & Smith, LLC Announces Investigation of King Pharmaceuticals	BU
13/10/10	KING PHARMA : Finkelstein Thompson LLP Announces Investigation of King Pharmaceuticals Inc.	BU
13/10/10	KING PHARMA : Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of King Pharmaceuticals, Inc.	BU
12/10/10	KING PHARMA : Ryan & Maniskas, LLP Announces Investigation of King Pharmaceuticals Inc.	BU
12/10/10	KING PHARMA : The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of King Pharmaceuticals, Inc. by Pfizer, Inc.	BU
12/10/10	KING PHARMA : King Pharmaceuticals Buyout Investigated for Shareholders by Goldfarb Branham Law Firm LLP	BU
12/10/10	KING PHARMA : The Briscoe Law Firm Investigates King Pharmaceuticals, Inc. for Shareholders Concerning the Buy-Out by Pfizer Inc.	BU
12/10/10	KING PHARMA : The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into the Possible Breaches of Fiduciary Duty by the Board of King Pharmaceuticals, Inc. in Connection with the Sale of the Company to Pfizer, Inc. – NYSE:KG	BU
12/10/10	KING PHARMA : Kendall Law Group Investigates King Pharmaceuticals, Inc. Acquisition for Shareholders	BU
12/10/10	KING PHARMA : Pfizer to Acquire King Pharmaceuticals, Inc.	PR
22/04/10	KING PHARMA : Acura Pharmaceuticals and King Pharmaceuticals Provide Update on FDA Advisory Committee Meeting For Acurox(R)	PR
07/04/10	KING PHARMA : DURECT Corporation Announces Commencement of Phase IIb ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) Clinical Trial by King Pharmaceuticals	PR
03/02/10	KING PHARMA : King Launches PainBalance(R): Educational Initiative to Help Reduce the Burden of Pain	PR
27/08/09	KING PHARMA : DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)	PR
13/08/09	KING PHARMA : Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain	PR
07/07/09	KING PHARMA : King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan	PR
02/07/09	KING PHARMA : Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)	PR
25/06/09	KING PHARMACEUTICA COM NPV : King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use	PR
30/11/-1	KING PHARMCUTCL : DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology	PR
30/11/-1	King Pharmaceuticals : King Pharmaceuticals Reports Plan to File a Motion for Rehearing and Rehearing En Banc	BU
30/11/-1	King Pharmaceuticals : King Pharmaceuticals Reports Filing of Paragraph IV Certification Pertaining to AVINZA(R)	BU
30/11/-1	King Pharmaceuticals : King Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference	BU
30/11/-1	King Pharmaceuticals : King Pharmaceuticals Announces That It is Now Distributing Bicillin(R) C-R Manufactured at Its Michigan Facility	BU